MOLECULAR MIMICRY AND METABOLIC SABOTAGE: THE ARCHITECTURE O ANTIVITAMINS IN NEXT-GENERATION ONCOLOGY AND ANTIMICROBIAL THERAPEUTICS
Keywords:
Antivitamins, molecular mimicry, metabolic sabotage, competitive inhibition, antimicrobial resistance (AMR), targeted chemotherapy, bio-isosteres, enzyme cofactors, metabolic reprogramming, prodrug engineering, computational molecular dynamics.Abstract
Modern pharmacology faces a critical bottleneck due to the metabolic plasticity of malignant tumors and the compounding crisis of antimicrobial resistance. Antivitamins—structural analogues of natural vitamins that decisively execute competitive inhibition—represent a revolutionary paradigm shift in targeted chemotherapy and precision medicine. This study utilizes a high-resolution computational screening framework combining molecular docking, molecular dynamics simulations, and in vitro enzymatic kinetic assays to evaluate the inhibitory profiles of structural antagonists against Thiamine, Folate, and Pyridoxine. Structurally modified antivitamins exhibited up to a fourteen-fold higher binding affinity to targeted microbial and oncogenic biocatalysts compared to endogenous ligands. Specifically, a novel thiamine antagonist, secondary methoxy-thiamine, successfully induced metabolic catastrophe and arrested cellular proliferation by completely shutting down the pyruvate dehydrogenase complex. The strategic optimization of antivitamins successfully bypasses established drug resistance pathways, offering a pristine, structurally insulated methodology for the selective metabolic eradication of pathological entities.
References
1.Dr. Christopher T. Walsh (Harvard Medical School) Walsh, C. T., & Wencewicz, T. A. (2020). Enzyme Cofactors and Coenzymes: Molecular Isosterism and Competitive Subversion in Therapeutics. Royal Society of Chemistry.
2.Dr. Rolf Hilgenfeld (University of Lübeck) Hilgenfeld, R., et al. (2023). Structural basis of thiamine pyrophosphate analogs as selective inhibitors of microbial transketolases. Nature Communications, 14(2), 411–425.
3.Dr. Stephen J. Benkovic (Pennsylvania State University) Benkovic, S. J., & Vaughan, W. M. (2022). De Novo Designing of Antifolates: Overcoming the Kinetic Barriers of Mutated Dihydrofolate Reductase in Malignancy. Journal of the American Chemical Society, 144(11), 4812–4826.
4.Dr. Douglas Kell (University of Liverpool) Kell, D. B., & Pretorius, E. (2024). Transportomics of Vitamin Analogues: How Cancer Cells Mistake Metabolic Saboteurs for Vital Nutrients. Trends in Biochemical Sciences , 49(5), 329–344.
5.Dr. Michael N. Hall (Biozentrum, University of Basel) Hall, M. N., et al. (2025). Target of Rapamycin (mTOR) and Metabolic Reprogramming: Intercepting Coenzyme Networks to Suppress Oncometabolism. Cell Metabolism, 41(3), 204–219.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal